Optimized DNA sequence encoding mature chain of human Vascular endothelial growth factor receptor 2 (VEGFR2) (MET1-GLU764) including an IgG1 Fc tag was expressed in HEK293 cells.
Recombinant human VEGFR2 (FLK-1) is a homodimer protein consisting of 2x770 amino acid residue subunits,due to glycosylation migrates as an approximately 160kDa band protein on reduced SDS-PAGE.
>95%, as determined by SDS-PAGE and HPLC
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).
The activity was tested by the ability to inhibit proliferation of HUVEC cells. The ED50 measured for this effect i 10-40 ng/ml
Recombinant human Vascular endothelial growth factor receptor 2 (VEGFR2) is lyophilized from 0.2 μm filtered PBS solution, pH7.2 , 5% Trehalose.
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.
Recombinant VEGFR2 (FLK-1) can be stored in working aliquots at 2° - 8° C for one month, or at -20°C to -70°C for twelve months.
Avoid repeated freeze/thaw cycles.
This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
VEGFR-2 is a member of a
broader family of receptor
tyrosine kinases consisting
the VEGFR1, 2, and 3 also
known as flt-1, KDR, and
flt-4. This is a family of
kinase receptors with 7 Ig
domains. Ligands such as
VEGF-A and placental growth
factor bind the VEGFRs
domains 2 and 3, with domain
2 making the primary contact
and domain 3 determining the
specificity of binding.
evidence for g-quadruplex in the promoter of VEGFR-2 and its targeting to inhibit tumor angiogenesis
Nucleic Acids Res.,
lysine methylation promotes VEGFR-2 activation and angiogenesis
a heterodimeric fc-based bispecific antibody simultaneously targeting VEGFR-2 and met exhibits potent antitumor activity
Mol. Cancer Ther.,
2748 - 2759.
static, but not cyclic tensional forces on the heart increase anti-angiogenic sflt-1 expression in endothelial cells and inhibit VEGFR-2 activation
Eur. Heart J.,
inhibition of VEGFR-2 reverses type 1 diabetes in nod mice by abrogating insulitis and restoring islet function
2870 - 2878.